

Global Controlled Release Drug Delivery Market, Drug Dosage, Price & Clinical Pipeline Insight 2029

<https://marketpublishers.com/r/G99CDF572B47EN.html>

Date: September 2023

Pages: 900

Price: US\$ 3,000.00 (Single User License)

ID: G99CDF572B47EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Controlled Release Drug Delivery Market, Drug Dosage, Price & Clinical Pipeline Insight 2029 Report Findings:

Global Controlled Release Drugs Delivery Market Opportunity: > USD 100 Billion By 2029

Insight On Drugs Commercially Available In Market: > 150 Drugs

Global Controlled Release Drug Clinical Trials Insight: > 230 Drugs

Controlled Release Drug Clinical Trials Insight By Company, Country , Indication & Phase

Drug Dosage, Patent, Pricing & Sales Insight By Indication

Global Controlled Release Drug Regional Market Trends: USA, Europe, Japan, China Canada & South Korea

Insight On Key 30 Companies

The concept of controlled release formulations in the pharmaceutical market is a rapidly emerging trend, attracting significant investments from key market players. To combat generic competition, pharmaceutical companies are actively developing sustained

release and controlled release versions of their popular drugs, thereby driving the market forward. The administration of controlled release drugs offers several advantages, including reduced dosage and frequency, minimized fluctuations in drug levels, enhanced efficacy, improved patient adherence, and consistent therapeutic effects. By utilizing controlled release drug delivery systems, drugs can be released at specific target sites at predetermined intervals, resulting in predictable release kinetics and prolonged therapeutic benefits compared to conventional administration methods. As a result of these additional advantages, the use of controlled release delivery systems is expected to experience significant growth in the forecast period.

Traditional immediate release formulations often fail to provide the desired pharmacokinetic profiles required for optimal treatment. However, the advent of controlled release drug delivery systems has revolutionized the way medications are administered. These innovative approaches offer numerous advantages, including sustained drug release, targeted delivery, and improved patient compliance. In this article, we delve into the world of controlled release drug delivery and explore its significant impact on patient care. One of the key benefits of controlled release drug delivery systems is their ability to improve drug efficacy. By maintaining sustained therapeutic drug levels, these systems ensure a consistent and prolonged action of the medication. This is particularly crucial for the treatment of chronic conditions or diseases that require continuous drug exposure. Controlled release systems can help achieve therapeutic concentrations over extended periods, effectively managing symptoms, and improving long-term outcomes.

Many medications display a narrow therapeutic window, meaning that the optimal dose lies between a range where efficacy is achieved without causing excessive side effects. Immediate-release formulations can lead to rapid drug absorption, resulting in high peak concentrations that may contribute to adverse reactions. Controlled release systems, on the other hand, offer a more controlled and gradual release of the drug, minimizing peak concentrations and reducing the risk of side effects. By providing a more stable drug concentration, these systems contribute to a better tolerability profile, ensuring patient safety and comfort.

Keeping to prescribed medication regimens is a crucial factor in achieving successful treatment outcomes. However, the need for frequent dosing can often pose challenges for patients, leading to non-compliance. Controlled release drug delivery systems address this issue by reducing the dosing frequency. Patients can benefit from prolonged drug action, resulting in fewer administrations and enhanced convenience. This improved compliance not only simplifies treatment regimens but also enhances

patient satisfaction and overall treatment success. In many disease conditions, it is desirable to deliver drugs specifically to the affected tissues or cells, while minimizing exposure to healthy tissues. Controlled release drug delivery systems enable targeted drug delivery by employing various strategies. Nanoparticles, liposomes, and other carrier systems can be engineered to specifically accumulate in the desired site, such as tumor tissues in cancer therapy. This targeted approach enhances drug efficacy while reducing off-target effects, ultimately leading to improved therapeutic outcomes.

The field of controlled release drug delivery continues to evolve, with ongoing advancements in technology and research. Scientists are exploring novel materials, such as stimuli responsive polymers, that can release drugs in response to specific triggers within the body. Additionally, the integration of smart sensors and monitoring devices in these systems holds the potential for personalized medicine, enabling real-time feedback and adaptive drug release. These innovations have the potential to revolutionize disease management and bring about a new era of precision medicine.

Controlled release drug delivery systems have revolutionized patient care by providing sustained and targeted drug delivery, optimizing treatment outcomes, and improving quality of life. From enhancing drug efficacy to reducing side effects and improving patient compliance, these systems have significantly advanced the field of pharmacotherapy. As researchers continue to push the boundaries of innovation, we can anticipate further breakthroughs that will shape the future of controlled release drug delivery, bringing us closer to personalized, effective, and safer therapeutic interventions for a wide range of medical conditions.

Contents

1. INTRODUCTION TO CONTROLLED DRUG DELIVERY

- 1.1 Fundamentals & Technology Of Controlled Drug Delivery Systems
- 1.2 Controlled Drug Delivery Classification: By System, Route & Technology
- 1.3 Controlled Drug Delivery Mechanism of Action

2. MATERIAL BASED APPROACHES FOR CONTROLLED DRUG DELIVERY

- 2.1 Polymers
- 2.2 Chronopharmaceutics
- 2.3 Nanoparticulate Delivery System

3. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET TRENDS

- 3.1 Current Market Scenario
- 3.2 Future Market Outlook

4. GLOBAL CONTROLLED RELEASE DRUG REGIONAL MARKET TRENDS

- 4.1 US
- 4.2 Europe
- 4.3 Japan
- 4.4 China
- 4.5 Canada
- 4.6 South Korea

5. GLOBAL CONTROLLED RELEASE DRUGS CLINICAL PIPELINE OVERVIEW

- 5.1 Company
- 5.2 Country
- 5.3 Drug Class
- 5.4 Indication
- 5.5 Patient Segment
- 5.6 Phase

6. CONTROLLED DRUG DELIVERY RESEARCH & CLINICAL TRENDS BY INDICATION

- 6.1 Diabetes
- 6.2 Cancer
- 6.3 Cardiovascular Diseases
- 6.4 Neurological Disorders
- 6.5 Infections

7. GLOBAL CONTROLLED RELEASE DRUGS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

- 7.1 Research
- 7.2 Preclinical
- 7.3 Phase-I
- 7.4 Phase-I/II
- 7.5 Phase-II
- 7.6 Phase-II/III
- 7.7 Phase-III
- 7.8 Preregistration
- 7.9 Registered

8. MARKETED CONTROLLED RELEASE DRUGS CLINICAL INSIGHT

9. CONTROLLED RELEASE DRUGS FOR ALZHEIMER'S DISEASE - PRICING, PATENT & DOSAGE INSIGHT

- 9.1 Namzaric (Extended-Release)
- 9.2 Namenda XR (Extended-Release)
- 9.3 Razadyne ER (Extended-Release)

10. CONTROLLED RELEASE DRUGS FOR PARKINSON'S DISEASE - PRICING, PATENT & DOSAGE INSIGHT

- 10.1 Gocovri (Extended-Release)
- 10.2 Osmolex ER (Extended-Release)
- 10.3 Mirapex ER (Extended-Release)

11. CONTROLLED RELEASE DRUGS FOR SCHIZOPHRENIA - PRICING, PATENT & DOSAGE INSIGHT

- 11.1 Perseris (Extended-Release)
- 11.2 Invega (Extended-Release)
- 11.3 Invega Sustenna/Invega Trinza/Invega Hafyera (Extended-Release)
- 11.4 Seroquel XR (Extended-Release)
- 11.5 Abilify Maintena/ Abilify Asimtufii (Extended-Release)
- 11.6 Aristada/Aristada Initio (Extended-Release)
- 11.7 Rykindo (Extended-Release)
- 11.8 Uzedy (Extended-Release)

12. CONTROLLED RELEASE DRUGS FOR CHRONIC PAIN - PRICING, PATENT & DOSAGE INSIGHT

- 12.1 Hysingla ER (Extended-Release)
- 12.2 Nucynta ER (Extended-Release)
- 12.3 Kadian (Extended-Release)
- 12.4 Xtampza ER (Extended-Release)
- 12.5 MS Contin (Extended-Release)
- 12.6 Embeda (Extended-Release)

13. CONTROLLED RELEASE DRUGS FOR MULTIPLE SCLEROSIS - PRICING, PATENT & DOSAGE INSIGHT

- 13.1 Ampyra/Fampyra (Extended-Release)
- 13.2 Tecfidera (Delayed-Release)
- 13.3 Rayos (Delayed-Release)
- 13.4 Vumerity (Delayed-Release)
- 13.5 Bafiertam (Delayed-Release)

14. CONTROLLED RELEASE DRUGS FOR DIABETES MELLITUS TYPE II - PRICING, PATENT & DOSAGE INSIGHT

- 14.1 Glumetza (Extended-Release)
- 14.2 Glucotrol XL (Extended-Release)
- 14.3 Glucophage XR (Extended-Release)
- 14.4 Bydureon (Extended-Release)
- 14.5 Trijardy XR (Extended-Release)

15. CONTROLLED RELEASE DRUGS FOR HYPERTENSION & ANGINA PECTORIS - PRICING, PATENT & DOSAGE INSIGHT

- 15.1 Procardia XL (Extended-Release)
- 15.2 Toprol XL (Extended-Release)
- 15.3 Adalat CC (Extended-Release)
- 15.4 Verelan PM (Extended-Release)
- 15.5 Cardizem LA (Extended-Release)

16. CONTROLLED RELEASE DRUGS FOR POST-OPERATIVE PAIN - PRICING, PATENT & DOSAGE INSIGHT

- 16.1 Zynrelef (Extended-Release)
- 16.2 Posimir (Sustained - Release)

17. CONTROLLED RELEASE DRUGS FOR HIV - PRICING, PATENT & DOSAGE INSIGHT

- 17.1 Apretude extended-release
- 17.2 Cabenuva extended-release
- 17.3 Rukobia (Extended-Release)

18. CONTROLLED RELEASE DRUGS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER - PRICING, PATENT & DOSAGE INSIGHT

- 18.1 Qelbree (extended-release)
- 18.2 Jornay PM (Extended-Release)
- 18.3 Cotelpla XR-ODT (Extended-Release)
- 18.4 Adzenys ER (Extended-Release)

19. CONTROLLED RELEASE DRUGS FOR INFLAMMATORY & AUTOIMMUNE DISEASES - PRICING, PATENT & DOSAGE INSIGHT

- 19.1 Rinvoq (Extended-Release)
- 19.2 Ortikos (Extended-Release)
- 19.3 Xeljanz XR (Extended-Release)

20. CONTROLLED RELEASE DRUGS FOR BACTERIAL INFECTIONS - PRICING, PATENT & DOSAGE INSIGHT

- 20.1 Aemcolo (Delayed-Release)

20.2 Talicia (Delayed-Release)

21. CONTROLLED RELEASE DRUGS FOR OPIOID USE DISORDER - PRICING, PATENT & DOSAGE INSIGHT

21.1 Sublocade (Sustained-Release)

21.2 Brixadi (Extended-Release)

22. CONTROLLED RELEASE DRUGS FOR PREVENTING ORGAN TRANSPLANT REJECTION - PRICING, PATENT & DOSAGE INSIGHT

22.1 Astagraf XL (Extended-Release)

22.2 Envarsus XR (Extended-Release)

23. GLOBAL CONTROLLED DRUG DELIVERY MARKET DYNAMICS

23.1 Market Drivers

23.2 Market Restraints

24. COMPETITIVE LANDSCAPE

24.1 AbbVie

24.2 Antlia Bioscience

24.3 Arbor Pharmaceuticals (Azurity Pharmaceuticals)

24.4 AstraZeneca

24.5 Bausch Health Companies

24.6 Biodexa Pharmaceuticals

24.7 Camurus

24.8 DURECT Corporation

24.9 Emplicure

24.10 Endo International

24.11 HLK Pharmacin

24.12 Jemincare

24.13 Johnson & Johnson

24.14 Luye Pharma Group

24.15 Lyndra

24.16 Mallinckrodt plc

24.17 MedinCell S.A.

24.18 Merck

- 24.19 Otsuka Pharmaceutical
- 24.20 Pacira BioSciences
- 24.21 Pfizer
- 24.22 Purdue Pharma
- 24.23 Roche
- 24.24 Sanofi
- 24.25 Serina Therapeutics
- 24.26 Sun Pharmaceutical Industries
- 24.27 Supernus Pharmaceuticals
- 24.28 Takeda
- 24.29 Tris Pharma
- 24.30 ViiV Healthcare

List Of Figures

LIST OF FIGURES

Figure 1-1: Limitations of Conventional Drug Delivery Systems

Figure 1-2: Diversification of Novel Drug Delivery Platforms

Figure 1-3: History of Drug Delivery Technology from First Generation till Third Generation

Figure 1-4: Barriers to be Overcome by Third Generation Drug Delivery System

Figure 1-5: Demonstration of Targeted & Non-Targeted Drug Delivery

Figure 1-6: Controlled Drug Release by Zero Order Mechanism

Figure 1-7: Plasma Concentration v/s Time Profile in Conventional & Controlled Release

Figure 1-8: Comparison of Various Modified Drug Release Systems

Figure 1-9: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap

Figure 1-10: Classification Based On Technicality Erudition

Figure 1-11: Structural Differentiation among Different Classified Drug Delivery Systems

Figure 1-12: Classification Based on Route of Administration

Figure 1-13: Differentiation of the Two Diffusion Controlled Mechanisms

Figure 1-14: Mechanism of Encapsulation Dissolution Controlled System

Figure 1-15: Osmotic Release of Drug with Controlled Mechanism

Figure 1-16: Illustration of Erosion Mechanisms Found in Matrix Systems

Figure 2-1: Categorization of Polymeric Controlled Drug Delivery Devices

Figure 2-2: Various Nanostructures Available for Nanoparticulate Delivery System

Figure 3-1: Global – Controlled Release Drug Delivery Market Size (US\$ Billion), 2019 - 2022

Figure 3-2: Global – Controlled Release Drug Delivery Market Forecast (US\$ Billion), 2023 - 2029

Figure 4-1: US –Controlled Release Market Size (US\$ Billion), 2019 - 2029

Figure 4-2: US – Population Above & Below 65 Years of Age (%), 2022

Figure 4-3: Europe –Controlled Release Drug Delivery Market Size (US\$ Billion), 2019 - 2029

Figure 4-4: EU – Population Above & Below 65 Years (%), 2022

Figure 4-5: Japan – Population Above & Below 65 Years (%), 2022

Figure 4-6: China – Population Above & Below 65 Years (%), 2022

Figure 5-1: Global - Controlled Release Drug Clinical Pipeline by Company (Number), 2023 Till 2029

Figure 5-2: Global - Controlled Release Drug Clinical Pipeline by Country (Number), 2023 Till 2029

Figure 5-3: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2023 Till 2029

Figure 5-4: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2023 Till 2029

Figure 5-5: Global - Controlled Release Drug Clinical Pipeline by Patient Segment (Number), 2023 Till 2029

Figure 5-6: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2023 Till 2029

Figure 6-1: Major Non-Invasive Administrative Routes of Insulin Delivery

Figure 6-2: Controlled Drug Delivery Approaches in Cancer Therapeutics

Figure 6-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS

Figure 9-1: Namzaric – Price of Oral Capsule, Extended Release of Different Dosages (US\$), September'2023

Figure 9-2: Namenda XR – Available Dosage Strengths (mg)

Figure 9-3: Namenda XR – Price of 30 Oral Capsules, Extended Release of Dosages (US\$), September'2023

Figure 9-4: Namenda XR – Price of 90 Extended-Release Oral Capsules of Dosage 14 mg, 28 mg (US\$), September'2023

Figure 9-5: Razadyne ER – Available Dosage Strengths (mg)

Figure 9-6: Razadyne ER – Price of Oral Capsule, Extended Release of Dosage 8 mg, 16 mg, 24 mg (US\$), September'2023

Figure 10-1: Gocovri XR – Available Dosage Strengths (mg)

Figure 10-2: Gocovri – Price of Extended Release Oral Capsules of Dosage 68.5 mg & 137 mg (US\$), September'2023

Figure 10-3: Global - Gocovri Annual Sales (US\$ Million), 2022-2023

Figure 10-4: Global - Gocovri Quarterly Sales (US\$ Million), H1'2023

Figure 10-5: Global - Gocovri Quarterly Sales (US\$ Million), 2022

Figure 10-6: Osmolex ER – Available Dosage Strengths (mg)

Figure 10-7: Osmolex ER – Price of Oral Capsule, Extended Release (US\$), September'2023

Figure 10-8: Mirapex ER – Available Dosage Strengths (mg)

Figure 10-9: Mirapex ER – Price of Oral Tablet, Extended Release (US\$), September'2023

Figure 11-1: Perseris: Available Dosage Strengths (mg)

Figure 11-2: Perseris - Price of Subcutaneous Powder for Injection, Extended Release (US\$) September'2023

Figure 11-3: Global - Perseris Annual Sales (US\$ Millions), 2019-2022

Figure 11-4: Global - Perseris Quarterly Sales (US\$ Millions), H1'2023

Figure 11-5: Global - Perseris Quarterly Sales (US\$ Millions), 2022

Figure 11-6: Invega – Available Dosage Strengths (mg)

Figure 11-7: Invega – Price of Oral Tablets, Extended Release of Dosage 1.5 mg, 3 mg & 6mg (US\$), September'2023

Figure 11-8: Invega – Price of Oral Tablets, Extended Release of Dosage 9 mg (US\$), September'2023

Figure 11-9: Invega Sustenna – Price of Extended Release Intramuscular Suspensions of Different Doses (US\$), September'2023

Figure 11-10: Invega Trinza – Price of Extended Release Intramuscular Suspensions of Different Doses (US\$), September'2023

Figure 11-11: Invega Hafyera – Price of Extended Release Intramuscular Suspensions of Different Doses (US\$), September'2023

Figure 11-12: Global - Invega Sustenna/Invega Trinza Annual Sales (US\$ Million), 2019-2023*

Figure 11-13: US - Invega Sustenna/Invega Trinza Annual Sales (US\$ Million), 2019-2023*

Figure 11-14: ROW - Invega Sustenna/Invega Trinza Annual Sales (US\$ Million), 2019-2023*

Figure 11-15: Global - Invega Sustenna/ Invega Trinza Quarterly Sales (US\$ Million), H1'2023

Figure 11-16: US - Invega Sustenna/ Invega Trinza Quarterly Sales (US\$ Million), H1'2023

Figure 11-17: ROW - Invega Sustenna/ Invega Trinza Quarterly Sales (US\$ Million), H1'2023

Figure 11-18: Global - Invega Sustenna/ Invega Trinza Quarterly Sales (US\$ Million), 2022

Figure 11-19: US - Invega Sustenna/ Invega Trinza Quarterly Sales (US\$ Million), 2022

Figure 11-20: ROW - Invega Sustenna/ Invega Trinza Quarterly Sales (US\$ Million), 2022

Figure 11-21: Seroquel XR – Available Dosage Strengths (mg)

Figure 11-22: Seroquel XR – Prices of Oral Tablets, Extended Release of Different Doses (US\$), September'2023

Figure 11-23: Global - Seroquel XR Total Annual Sales (US\$ Million), 2019 - 2021

Figure 11-24: Abilify Maintena – Available Dosage Strengths (mg)

Figure 11-25: Abilify Maintena – Price of Intramuscular Powder for Injection, Extended Release (US\$), September'2023

Figure 11-26: Abilify Asimtufii – Price of Intramuscular Powder for Injection, Extended Release (US\$), September'2023

Figure 11-27: Global – Abilify Maintena Annual Sales (US\$ Million), 2019-2021

Figure 11-28: Global – Abilify Maintena Quarterly Sales (US\$ Million), H1'2023

Figure 11-29: Global – Abilify Maintena Quarterly Sales (US\$ Million), 2022

Figure 11-30: Aristada – Available Dosage Strengths (mg)

Figure 11-31: Aristada – Price of Intramuscular Suspension, Extended Release of Different Doses (US\$), September'2023

Figure 11-32: Aristada Initio – Price of Intramuscular Suspension, Extended Release of Dose 675 mg/2.4 mL (US\$), September'2023

Figure 11-33: Global - Aristada Annual Sales (US\$ Million), 2019-2023*

Figure 11-34: Global - Aristada Quarterly Sales (US\$ Million), H1'2023

Figure 11-35: Global - Aristada Quarterly Sales (US\$ Million), 2022

Figure 11-36: Rykindo – Available Dosage Strengths (mg)

Figure 11-37: Uzedy – Available Dosage Strengths (mg)

Figure 11-38: Uzedy – Prices of Oral Tablets, Extended Release of Different Doses (US\$), September'2023

Figure 12-1: Hysingla ER – Available Dosage Strengths (mg)

Figure 12-2: Hysingla ER – Price of Oral Tablet, Extended Release of Different Doses (US\$), September'2023

Figure 12-3: Nucynta ER – Available Dosage Strengths (mg)

Figure 12-4: Nucynta ER - Price of Oral Tablets, Extended Release of Different Doses (US\$), September'2023

Figure 12-5: Global - Nucynta ER Annual Sales (US\$ Million), 2019-2023*

Figure 12-6: Global - Nucynta ER Quarterly Sales (US\$ Million), H1'2023

Figure 12-7: Global - Nucynta ER Quarterly Sales (US\$ Million), 2022

Figure 12-8: Kadian – Available Dosage Strengths (mg)

Figure 12-9: Kadian – Price of Oral Capsules, Extended Release of Dosage 10 mg/12 hr (US\$), September'2023

Figure 12-10: Kadian – Price of Oral Capsules, Extended Release of Dosage 10 mg/12 to 24 hr & 10 mg/24 hr (US\$), September'2023

Figure 12-11: Kadian – Price of Oral Capsules, Extended Release of Dosage 20 mg/12 hr (US\$), September'2023

Figure 12-12: Kadian – Price of Oral Capsules, Extended Release of Dosage 20 mg/12 to 24 hr & 20 mg/24 hr (US\$), September'2023

Figure 12-13: Kadian – Price of Oral Capsules, Extended Release of Dosage 30 mg/12 hr (US\$), September'2023

Figure 12-14: Kadian – Price of Oral Capsules, Extended Release of Dosage 30 mg/12 to 24 hr & 30 mg/24 hr (US\$), September'2023

Figure 12-15: Kadian – Price of Oral Capsules, Extended Release of Dosage 40 mg/12 to 24 hr & 40 mg/24 hr (US\$), September'2023

Figure 12-16: Kadian – Price of Oral Capsules, Extended Release of Dosage 50 mg/12 hr (US\$), September'2023

Figure 12-17: Kadian – Price of Oral Capsules, Extended Release of Dosage 50 mg/12 to 24 hr & 50 mg/24 hr (US\$), September'2023

Figure 12-18: Kadian – Price of Oral Capsules, Extended Release of Dosage 60 mg/12 hr (US\$), September'2023

Figure 12-19: Kadian – Price of Oral Capsules, Extended Release of Dosage 60 mg/12 to 24 hr (US\$), September'2023

Figure 12-20: Kadian – Price of Oral Capsules, Extended Release of Dosage 60 mg/24 hr (US\$), September'2023

Figure 12-21: Kadian – Price of Oral Capsules, Extended Release of Dosage 70 mg/12 to 24 hr (US\$), September'2023

Figure 12-22: Kadian – Price of Oral Capsules, Extended Release of Dosage 80 mg/12 hr, 80 mg/12 to 24 hr & 80 mg/24 hr (US\$), September'2023

Figure 12-23: Kadian – Price of Oral Capsules, Extended Release of Dosage 100 mg/12 hr, 100 mg/12 to 24 hr & 100 mg/24 hr (US\$), September'2023

Figure 12-24: Kadian – Price of Oral Capsules, Extended Release of Dosage 130 mg/12 to 24 hr & 150 mg/12 to 24 hr (US\$), September'2023

Figure 12-25: Kadian – Price of Oral Capsules, Extended Release of Dosage 200 mg/12 to 24 hr & 200 mg/24 hr (US\$), September'2023

Figure 12-26: Xtampza ER – Available Dosage Strengths (mg)

Figure 12-27: Xtampza ER - Price of Oral Capsules, Extended Release of Different Doses (US\$), September'2023

Figure 12-28: Global - Xtampza ER Annual Sales (US\$ Million), 2019-2023*

Figure 12-29: Global - Xtampza ER Quarterly Sales (US\$ Million), H1'2023

Figure 12-30: Global - Xtampza ER Quarterly Sales (US\$ Million), 2022

Figure 12-31: MS Contin – Available Dosage Strengths (mg)

Figure 12-32: MS Contin - Price of Oral Tablet, Extended Release of Dosage 15 mg/ 8 to 12 hr (US\$), September'2023

Figure 12-33: Embeda - Price of Oral Capsules, Extended Release of Different Doses (US\$), September'2023

Figure 13-1: Ampyra – Price of Oral Tablet, Extended Release of Dosage 10 mg (US\$), September'2023

Figure 13-2: Ampyra/ Fampyra - Global Annual Sales (US\$ Million), 2019-2023*

Figure 13-3: Ampyra/ Fampyra - Global Quarterly Sales (US\$ Million), H1'2023

Figure 13-4: Ampyra/ Fampyra - Global Quarterly Sales (US\$ Million), 2022

Figure 13-5: Tecfidera – Available Dosage Strengths (mg)

Figure 13-6: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 120 mg (US\$), September'2023

Figure 13-7: Global - Tecfidera Annual Sales (US\$ Million), 2019-2023*

Figure 13-8: US - Tecfidera Annual Sales (US\$ Million), 2019-2023*

- Figure 13-9: ROW - Tecdifera Annual Sales (US\$ Million), 2019-2023*
- Figure 13-10: Global - Tecdifera Quarterly Sales (US\$ Million), H1'2023
- Figure 13-11: US - Tecdifera Quarterly Sales (US\$ Million), H1'2023
- Figure 13-12: ROW - Tecdifera Quarterly Sales (US\$ Million), H1'2023
- Figure 13-13: Global - Tecdifera Quarterly Sales (US\$ Million), 2022
- Figure 13-14: US - Tecdifera Quarterly Sales (US\$ Million), 2022
- Figure 13-15: ROW - Tecdifera Quarterly Sales (US\$ Million), 2022
- Figure 13-16: Rayos – Available Dosage Strengths (mg)
- Figure 13-17: Rayos - Price of Oral Tablet, Delayed Release of All Dosages (US\$), September'2023
- Figure 13-18: US - Rayos Annual Sales (US\$ Million), 2019-2023*
- Figure 13-19: Global - Rayos Quarterly Sales (US\$ Million), H1'2023
- Figure 13-20: Global - Rayos Quarterly Sales (US\$ Million), 2022
- Figure 13-21: Vumerity – Price of Oral Capsule, Delayed Release (US\$), September'2023
- Figure 13-22: Global - Vumerity Annual Sales (US\$ Million), 2019-2023*
- Figure 13-23: US - Vumerity Annual Sales (US\$ Million), 2019-2023*
- Figure 13-24: ROW - Vumerity Annual Sales (US\$ Million), 2019-2023*
- Figure 13-25: Global - Vumerity Quarterly Sales (US\$ Million), H1'2023
- Figure 13-26: US - Vumerity Quarterly Sales (US\$ Million), H1'2023
- Figure 13-27: ROW - Vumerity Quarterly Sales (US\$ Million), H1'2023
- Figure 13-28: Global - Vumerity Quarterly Sales (US\$ Million), 2022
- Figure 13-29: US - Vumerity Quarterly Sales (US\$ Million), 2022
- Figure 13-30: ROW - Vumerity Quarterly Sales (US\$ Million), 2022
- Figure 13-31: Bafiertam – Price of Oral Capsule, Delayed Release (US\$), September'2023
- Figure 14-1: Glumetza – Available Dosage Strengths (mg)
- Figure 14-2: Glumetza - Price of Oral Tablets, Extended Release of Dosage 500 mg (US\$), September'2023
- Figure 14-3: Glumetza - Price of Glumetza Oral Tablets, Extended Release of Dosage 1000 mg (US\$), September'2023
- Figure 14-4: Glucotrol XL – Available Dosage Strengths (mg)
- Figure 14-5: Glucotrol XL – Price Oral Tablets Extended Release of Dosage 2.5 mg (US\$), September'2023
- Figure 14-6: Glucotrol XL - Price of Oral Tablets Extended Release of Dosages 5 mg & 10 mg (US\$), September'2023
- Figure 14-7: Glucotrol XL - Price of Oral Tablets Extended Release of Dosage 5 mg (US\$), September'2023
- Figure 14-8: Glucophage XR – Available Dosage Strengths (mg)

Figure 14-9: Glucophage XR - Price of Oral Tablet, Extended Release of Dosage 500 mg (US\$), September'2023

Figure 14-10: Glucophage XR - Price of Oral Tablet, Extended Release of Dosage 750 mg (US\$), September'2023

Figure 14-11: Bydureon - Price of Powder for Injection of Dosage 2 mg (US\$), September'2023

Figure 14-12: Global – Bydureon Annual Sales (US\$ Million), 2019-2023

Figure 14-13: US – Bydureon Annual Sales (US\$ Million), 2019-2023

Figure 14-14: EU – Bydureon Annual Sales (US\$ Million), 2019-2023

Figure 14-15: ROW – Bydureon Annual Sales (US\$ Million), 2019-2023

Figure 14-16: Global – Bydureon Quarterly Sales (US\$ Million), H1'2023

Figure 14-17: US – Bydureon Quarterly Sales (US\$ Million), H1'2023

Figure 14-18: EU – Bydureon Quarterly Sales (US\$ Million), H1'2023

Figure 14-19: ROW – Bydureon Quarterly Sales (US\$ Million), H1'2023

Figure 14-20: Global – Bydureon Quarterly Sales (US\$ Million), 2022

Figure 14-21: US – Bydureon Quarterly Sales (US\$ Million), 2022

Figure 14-22: EU – Bydureon Quarterly Sales (US\$ Million), 2022

Figure 14-23: ROW – Bydureon Quarterly Sales (US\$ Million), 2022

Figure 14-24: Trijardy XR - Price of Oral Tablet, Extended Release of Dosage 10 mg-5 mg-1000 mg & 25 mg-5 mg-1000 mg (US\$), September'2023

Figure 14-25: Trijardy XR - Price of Oral Tablet, Extended Release of Dosage 12.5 mg-2.5 mg-1000 mg & 5 mg-2.5 mg-1000 mg (US\$), September'2023

Figure 15-1: Procardia XL – Available Dosage Strengths (mg)

Figure 15-2: Procardia XL - Price of Oral Tablet, Extended Release of Dosage 30 mg (US\$), September'2023

Figure 15-3: Procardia XL - Price of Oral Tablet, Extended Release of Dosage 60 mg (US\$), September'2023

Figure 15-4: Procardia XL - Price of Oral Tablet, Extended Release of Dosage 90 mg (US\$), September'2023

Figure 15-5: Toprol XL – Available Dosage Strengths

Figure 15-6: Toprol XL - Price of Oral Tablet, Extended Release of Dosage 25 mg & 50 mg (US\$), September'2023

Figure 15-7: Toprol XL - Price of Oral Tablet, Extended Release of Dosage 100 mg (US\$), September'2023

Figure 15-8: Toprol XL - Price of Oral Tablet, Extended Release of Dosage 200 mg (US\$), September'2023

Figure 15-9: Global – Toprol XL Annual Sales (US\$ Million), 2019-2023

Figure 15-10: US – Toprol XL Annual Sales (US\$ Million), 2019-2023

Figure 15-11: EU – Toprol XL Annual Sales (US\$ Million), 2019-2023

- Figure 15-12: ROW – Toprol XL Annual Sales (US\$ Million), 2019-2023
- Figure 15-13: Global – Toprol XL Quarterly Sales (US\$ Million), H1'2023
- Figure 15-14: US – Toprol XL Quarterly Sales (US\$ Million), H1'2023
- Figure 15-15: EU – Toprol XL Quarterly Sales (US\$ Million), H1'2023
- Figure 15-16: ROW – Toprol XL Quarterly Sales (US\$ Million), H1'2023
- Figure 15-17: Global – Toprol XL Quarterly Sales (US\$ Million), 2022
- Figure 15-18: EU – Toprol XL Quarterly Sales (US\$ Million), 2022
- Figure 15-19: ROW – Toprol XL Quarterly Sales (US\$ Million), 2022
- Figure 15-20: Adalat CC – Available Dosage Strengths (mg)
- Figure 15-21: Adalat CC - Price of Oral Tablet Extended Release of Dosage 30 mg (US\$), September'2023
- Figure 15-22: Adalat CC - Price of Oral Tablet Extended Release of Dosage 60 mg (US\$), September'2023
- Figure 15-23: Adalat CC - Price of Oral Tablet Extended Release of Dosage 90 mg (US\$), September'2023
- Figure 15-24: Verelan PM – Available Dosage Strengths (mg)
- Figure 15-25: Verelan PM - Price of Oral Capsule, Extended Release of Dosage 200 mg/24 hr (US\$), September'2023
- Figure 15-26: Verelan PM - Price of Oral Capsule, Extended Release of Dosage 300 mg/24 hr (US\$), September'2023
- Figure 15-27: Cardizem LA – Available Dosage Strengths (mg)
- Figure 15-28: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US\$), September'2023
- Figure 15-29: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US\$), September'2023
- Figure 15-30: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US\$), September'2023
- Figure 15-31: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US\$), September'2023
- Figure 15-32: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US\$), September'2023
- Figure 15-33: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US\$), September'2023
- Figure 16-1: Zynrelef - Price of Injectable Solution, Extended Release of Different Dosages (US\$), September'2023
- Figure 16-2: Global – Zynrelef Annual Sales (US\$ Million), 2021-2023
- Figure 16-3: Global – Zynrelef Quarterly Sales (US\$ Million), H1'2023
- Figure 16-4: Global – Zynrelef Quarterly Sales (US\$ Million), 2022
- Figure 17-1: Aprelude - Price of Intramuscular Suspension, Extended Release of

Different Dosages (US\$), September'2023

Figure 17-2: Cabenuva - Price of injectable Suspension, Extended Release of Different Dosages (US\$), September'2023

Figure 17-3: Rukobia - Price of injectable Suspension, Extended Release of Different Dosages (US\$), September'2023

Figure 18-1: Qelbree – Available Dosage Strengths (mg)

Figure 18-2: Qelbree - Price of Oral Tablet, Extended Release of Dosages 100 mg & 150 mg (US\$), September'2023

Figure 18-3: Qelbree - Price of Oral Tablet, Extended Release of Dosage 200 mg (US\$), September'2023

Figure 18-4: Global – Qelbree Annual Sales (US\$ Million), 2021-2023

Figure 18-5: Global – Qelbree Quarterly Sales (US\$ Million), H1'2023

Figure 18-6: Global – Qelbree Quarterly Sales (US\$ Million), 2022

Figure 18-7: Jornay PM – Available Dosage Strengths (mg)

Figure 18-8: Jornay PM - Price of Oral Capsule, Extended Release (US\$), September'2023

Figure 18-9: Cotempla XR-ODT – Available Dosage Strengths (mg)

Figure 18-10: Cotempla XR-ODT - Price of Oral Capsule, Extended Release (US\$), September'2023

Figure 18-11: Adzenys XR-ODT – Available Dosage Strengths (mg)

Figure 18-12: Adzenys XR-ODT - Price of Oral Capsule, Extended Release (US\$), September'2023

Figure 18-13: Global – Adzenys XR-ODT & Cotempla XR-ODT Annual Sales (US\$ Million), 2021-2023

Figure 18-14: Global – Adzenys XR-ODT & Cotempla XR-ODT Quarterly Sales (US\$ Million), H1'2023

Figure 18-15: Global – Adzenys XR-ODT & Cotempla XR-ODT Quarterly Sales (US\$ Million), 2022

Figure 19-1: Rinvoq – Available Dosage Strengths (mg)

Figure 19-2: Rinvoq - Price of Oral Capsule, Extended Release of Doses 15 mg & 30 mg (US\$), September'2023

Figure 19-3: Rinvoq - Price of Oral Capsule, Extended Release of Doses 45 mg (US\$), September'2023

Figure 19-4: Global - Rinvoq Annual Sales (US\$ Million), 2019-2023*

Figure 19-5: US - Rinvoq Annual Sales (US\$ Million), 2019-2023*

Figure 19-6: ROW - Rinvoq Annual Sales (US\$ Million), 2019-2023*

Figure 19-7: Global - Rinvoq Quarterly Sales (US\$ Million), H1'2023

Figure 19-8: US - Rinvoq Quarterly Sales (US\$ Million), H1'2023

Figure 19-9: ROW - Rinvoq Quarterly Sales (US\$ Million), H1'2023

Figure 19-10: Global - Rinvoq Quarterly Sales (US\$ Million), 2022

Figure 19-11: US - Rinvoq Quarterly Sales (US\$ Million), 2022

Figure 19-12: ROW - Rinvoq Quarterly Sales (US\$ Million), 2022

Figure 19-13: Ortikos – Available Dosage Strengths (mg)

Figure 19-14: Ortikos - Price of Oral Capsule, Extended Release (US\$),
September'2023

Figure 19-15: Xeljanz XR – Available Dosage Strengths (mg)

Figure 19-16: Xeljanz XR - Price of Oral Capsule, Extended Release (US\$),
September'2023

Figure 19-17: Global – Xeljanz XR Annual Sales (US\$ Million), 2019-2023

Figure 19-18: US – Xeljanz XR Annual Sales (US\$ Million), 2019-2023

Figure 19-19: EU – Xeljanz XR Annual Sales (US\$ Million), 2019-2023

Figure 19-20: ROW – Xeljanz XR Annual Sales (US\$ Million), 2019-2023

Figure 19-21: Global – Xeljanz XR Quarterly Sales (US\$ Million), H1'2023

Figure 19-22: US – Xeljanz XR Quarterly Sales (US\$ Million), H1'2023

Figure 19-23: EU – Xeljanz XR Quarterly Sales (US\$ Million), H1'2023

Figure 19-24: ROW – Xeljanz XR Quarterly Sales (US\$ Million), H1'2023

Figure 19-25: Global – Xeljanz XR Quarterly Sales (US\$ Million), 2022

Figure 19-26: US – Xeljanz XR Quarterly Sales (US\$ Million), 2022

Figure 19-27: EU – Xeljanz XR Quarterly Sales (US\$ Million), 2022

Figure 19-28: ROW – Xeljanz XR Quarterly Sales (US\$ Million), 2022

Figure 20-1: Aemcolo - Price of Oral Capsule, Extended Release (US\$),
September'2023

Figure 20-2: Talicia - Price of Oral Capsule, Extended Release (US\$), September'2023

Figure 21-1: Sublocade - Price of Subcutaneous Solution, Extended Release (US\$),
September'2023

Figure 21-2: Global - Sublocade Annual Sales (US\$ Million), 2019-2023*

Figure 21-3: Global - Sublocade Quarterly Sales (US\$ Million), H1'2023

Figure 21-4: Global - Sublocade Quarterly Sales (US\$ Million), 2022

Figure 22-1: Astagraf XL – Available Dosage Strengths (mg)

Figure 22-2: Astagraf XL - Price of Oral Capsule, Extended Release (US\$),
September'2023

Figure 22-3: Envarsus XR – Available Dosage Strengths (mg)

Figure 22-4: Envarsus XR - Price of Oral Capsule, Extended Release of Dosage 0.75
mg (US\$), September'2023

Figure 22-5: Envarsus XR - Price of Oral Capsule, Extended Release of Dosage 1 mg
(US\$), September'2023

Figure 22-6: Envarsus XR - Price of Oral Capsule, Extended Release of Dosage 4 mg
(US\$), September'2023

Figure 23-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 23-2: Major Challenges Faced by Controlled Drug Delivery System

I would like to order

Product name: Global Controlled Release Drug Delivery Market, Drug Dosage, Price & Clinical Pipeline Insight 2029

Product link: <https://marketpublishers.com/r/G99CDF572B47EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G99CDF572B47EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

